AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 92 min read$ABEO

O'Malley Brendan M. sold $84K of ABEO

O'Malley Brendan M. (SVP, Chief Legal Officer) sold 12,050 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 on 2026-07-09.

Original reporting
SEC EDGAR · O'Malley Brendan M.
Published Jul 9, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Neutral
high confidence
Mentioned
$ABEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

This provides a fresh datapoint on insider activity but does not disclose new operational, financial, or regulatory developments for the issuer.

02

Market read

Traders may monitor for follow-on insider activity, but the transaction alone is unlikely to change valuation without additional company-specific catalysts.

03

What to watch

Insider sales can be driven by diversification, tax, or pre-existing personal liquidity needs, and the filing provides no rationale or linkage to company outlook.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-09 after-hours; relevant for monitoring next sessions.

Background

The article is an SEC Form 4 insider transaction for Abeona Therapeutics, reporting an open-market sale by the company’s SVP and Chief Legal Officer.

Company-level read

Ticker impact

$ABEONeutralHigh confidence
Context

Abeona Therapeutics Form 4 shows SVP Chief Legal Officer O'Malley sold 12,050 shares at $6.9637 on 2026-07-09.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment/flow rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not include new company performance, guidance, or material corporate events.

Market effects

Sector

Minimal; this is company-specific insider dealing with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • issuer
    ABEO

    Abeona Therapeutics Inc., the subject of the Form 4 insider transaction.

  • insider
    Brendan M. O'Malley

    SVP, Chief Legal Officer who sold 12,050 shares on 2026-07-09.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min